 |
인쇄하기
취소
|
Boryung launches new ulcer drug
Boryung Pharm said it has recently released Stogar (lafutidine), a newly developed histamine H(2)-receptor antagonist.
Stogar is indicated for treatment of Helicobacter pylori and inhibits daytime (i.e., postprandial) as well as nighttime gastric acid secretion in clinical studies.
Boryung examined the clinical efficacy of Stogar in local 37 hospitals and found that the effect of Stogar a...
Stogar is indicated for treatment of Helicobacter pylori and inhibits daytime (i.e., postprandial) as well as nighttime gastric acid secretion in clinical studies.
Boryung examined the clinical efficacy of Stogar in local 37 hospitals and found that the effect of Stogar a...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.